Press Release

Psoriasis Treatment Market Global Size, Key Companies, Trends, Growth and Regional Forecasts Research to 2026

Psoriasis Treatment Market Global Market Research report provides information regarding market size, share, trends, growth, cost structure, capacity, and revenue and forecast 2026

The increasing prevalence of psoriasis around the world is boosting the global psoriasis treatment market, says Fortune Business Insights in their recent report. The report is titled “Psoriasis Treatment Market: Global Market Analysis, Insights, and Forecasts, 2018 – 2025.” According to the report, the market will reach US$ 37,634.2 Mn by 2026 from US$ 18,378.0 Mn in 2018, exhibiting a CAGR of 8.2% between 2018 and 2026.

Key Players Operating in The Psoriasis Treatment Market Include:

Key players are involved in mergers and acquisition to strengthen their market position. Owing to increasing competition frequent innovations are taking place in the market. Some of the companies operating the industry are:

  • Merck & Co., Inc.,
  • LEO Pharma A/S,
  • Pfizer Inc.,
  • Sun Pharmaceutical Industries Ltd,
  • AbbVie Inc.,
  • UCB S.A.,
  • Amgen Inc.,
  • Johnson & Johnson Services, Inc.,
  • Eli Lilly and Company,

Request a Sample Copy of the Research Report: https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/psoriasis-treatment-market-100600

According to the report prepared by Fortune Business Insights, the TNF inhibitors segment emerged dominant among drug classes. In 2018, the TNF inhibitor segment held 46.3% share in the market. However, in the coming years, the market may witness higher demand for biosimilar version leading to the decline in the price of TNF inhibitors. This, accompanied by the increasing prescription volume for interleukin inhibitors segment may help the interleukin inhibitors to emerge as the dominant segment in the coming years.

Rising Prevalence of Plaque Psoriasis to Increase Demand for Treatment, Boosting Market

One of the major factor boosting the global psoriasis treatment market is the increasing prevalence of the disease itself. The World Health Organization states that the prevalence of psoriasis is estimated to vary between 0.09% to 11.0% across all nations. This ultimately means that psoriasis is a serious problem. Psoriasis can occur to anyone irrespective of age but is usually reported to occur to aged people between 50 to 70 years. The rising geriatric population and their vulnerability towards diseases such as psoriatic arthritis are factor propelling growth of the market. These, coupled with the rising prevalence of plaque psoriasis, are likely to create growth opportunities for the market in the forecast period.

The rising availability of biologic and biosimilar products is helping the market for psoriasis grow rapidly. Increase in prescription volume of the biologic products and favorable reimbursement policies by governments are also helping the market grow and continue doing so in the forecast duration as well.

North America to Continue Dominating Market with Rapid Adoption of Biological Therapy

Fortune Business Insights foresees the global psoriasis market to witness dominance of North America followed by Europe. As per the National Psoriasis Foundation, there are about 8 million people in America living with psoriasis. Owing to its quick rate of biological therapy adoption, and rise in investments on research and development for clinical trials, North America is likely to continue dominating the global market for psoriasis in the forecast period as well.

On the other side, the emerging markets in the Middle East and Africa, Latin America, and Asia Pacific are expected to offer lucrative growth opportunities because of large patient pool, the improving healthcare infrastructure and medical facilities; increasing awareness, and with rising investments for development of new therapeutics for psoriasis.

More Trending Topics from Fortune Business Insights:

Non-Hodgkin Lymphoma Treatment Market

Albumin Market 

Wound Closure Market

Dale Martinez

Dale possesses an engineering degree in Electronics from the Georgia Institute of Technology. She is the sole contributor at the Healthcare IT column. Before opting to write, Dale worked at major firms such as Microsoft, Amazon, GE, Raytheon, and so on. She possesses vast knowledge about a variety of fields like IT, IoT, Telecommunications, Health Dialysis, photovoltaic, and many others. Dale is also a ballet dancer.

Related Articles

Leave a Reply

Your email address will not be published. Required fields are marked *

Close